Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

16

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

16 results for “Lp-PLA2”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov36/100

Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans

ClinicalTrials.gov study NCT01067339. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Impact of an 8-week Linoleic Acid Intake in Soy Oil on Lp-PLA2 Activity in Healthy Adults

ClinicalTrials.gov study NCT02753907. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad28/100

Data from: Lp-PLA2 and dual antiplatelet agents in intracranial arterial stenosis

Objective: To evaluate the interaction effect of lipoprotein-associated phospholipase A2 (Lp-PLA2) activity on the efficacy and safety of dual/single antiplatelet therapy in patients with and without intracranial arterial stenosis (ICAS) by the Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial. Methods: Subjects with both MR imaging analysis and Lp-PLA2 testing results were included in the current subanalysis. The interaction of Lp-PLA2 activity with the effects of dual and single antiplatelet therapy were analyzed through cox proportional hazards regressions model. Results: Among the 797 patients, the mean age was 63.1±10.8 years, 518 (65%) were men, 356 (44.7%) patients had ICAS and 441 (55.3%) did not. There are significantly more patients with elevated Lp-PLA2 activity in the ICAS group than that in the non-ICAS group (43.8% versus 35.4%, p=0.02). There was significant interaction between Lp-PLA2 activity levels and the two antiplatelet therapy for prevention of stroke recurrences and combined vascular events even after adjustment for confounding factors exclusively for patients with ICAS (p=0.016, 0.016, respectively), but not for those without (p=0.289, 0.597, respectively). Compared with aspirin alone, dual antiplatelet therapy significantly reduced the risk of stroke recurrences and combined vascular events (adjusted hazard ratio=0.33 [0.12-0.88], p=0.026; 0.33 [0.12-0.88], p=0.026, respectively) for patients with both ICAS and non-elevated Lp-PLA2 activity. Conclusions: Presence of both ICAS and non-elevated Lp-PLA2 activity may predict better response to dual antiplatelet therapy in prevention of recurrent strokes and combined vascular events for patients with minor stroke or high-risk TIA.

opencc-zeroJul 2020View details →
zenodo28/100

Figure 3 from: Nafisah W, Dalilati AZ, Christina YI, Atho'illah MF, Rifa'ia M, Noor TNETA, Nugraha AP (2024) Amstirdam coffee ameliorates Lp-PLA2 and the inflammatory response in an atherosclerosis rats. Pharmacia 71: 1-8. https://doi.org/10.3897/pharmacia.71.e106817

Figure 3 ACE administration increased the level of regulatory T cells in mice fed a high-fat, high-fructose diet for 5 months. The level of regulatory T cell A. CD4+CD25+CD62L+ subsets, B. CD4+CD25+IL-10+ subsets, and C. CD4+CD25+TGF-+subsets of mice fed with HFFD and administration of ACE from flow cytometry analysis. The percentage of regulatory T cell D. CD4+CD25+CD62L+ subsets, E. CD4+CD25+IL-10+ subsets, and F. CD4+CD25+TGF-+ subsets of mice fed with HFFD and administered ACE The data are mean SD (n = 5). N: normal-fed mice (non-high-fat-fructose diet); HFFD: high-fat-fructose diet mice (w/o administration of ACE); D1: HFFD mice receiving ACE 104 mg/kg body weight; D2: HFFD mice receiving ACE 520 mg/kg body weight; D3: HFFD mice receiving ACE 5200 mg/kg body weight. The different notation on the chart was considered significantly different for each group at p<0.05 and vice versa on the DMRT post hoc test.

opencc-by-4.0Jan 2024View details →
zenodo28/100

Figure 5 from: Nafisah W, Dalilati AZ, Christina YI, Atho'illah MF, Rifa'ia M, Noor TNETA, Nugraha AP (2024) Amstirdam coffee ameliorates Lp-PLA2 and the inflammatory response in an atherosclerosis rats. Pharmacia 71: 1-8. https://doi.org/10.3897/pharmacia.71.e106817

Figure 5 The effect of ACE increased TGF-β production (CD4+TGF-β+) in mice fed with a high fat-fructose diet for 5 months. The expression of TGF-β (CD4+TGF-β+) of mice fed with HFFD and administration of ACE from flow cytometry analysis (Fig. 5G). The percentage of regulatory (CD4+IL-10+) of mice fed with HFFD and administration of ACE (Fig. 5H). Data are mean ± SD (n=5). N: normal fed mice (non-high fat-fructose diet), HFFD: high fat-fructose diet mice (w/o administration of ACE), D1: HFFD mice receiving ACE 104 mg/kg body weight, D2: HFFD mice receiving ACE 520 mg/kg BW, D3: HFFD mice receiving ACE 5200 mg/kg BW. The different notation on the chart was considered significantly different for each group at p < 0.05 and vice versa on DMRT post hoc test.

opencc-by-4.0Jan 2024View details →
zenodo28/100

Figure 2 from: Nafisah W, Dalilati AZ, Christina YI, Atho'illah MF, Rifa'ia M, Noor TNETA, Nugraha AP (2024) Amstirdam coffee ameliorates Lp-PLA2 and the inflammatory response in an atherosclerosis rats. Pharmacia 71: 1-8. https://doi.org/10.3897/pharmacia.71.e106817

Figure 2 ACE administration reduced foam cells in aorta histopathology (M = 400×) in mice fed a high-fat, high-fructose diet for 5 months. The black arrow shows the accumulation of foam cells in the tunica media, and the asterisk (*) shows the lumen of the aorta. N: normal-fed mice (non-high-fat-fructose diet); HFFD: high-fat-fructose diet mice (w/o administration of ACE); D1: HFFD mice receiving ACE 104 mg/kg body weight; D2: HFFD mice receiving ACE 520 mg/kg body weight; D3: HFFD mice receiving ACE 5200 mg/kg body weight.

opencc-by-4.0Jan 2024View details →
zenodo28/100

Figure 1 from: Nafisah W, Dalilati AZ, Christina YI, Atho'illah MF, Rifa'ia M, Noor TNETA, Nugraha AP (2024) Amstirdam coffee ameliorates Lp-PLA2 and the inflammatory response in an atherosclerosis rats. Pharmacia 71: 1-8. https://doi.org/10.3897/pharmacia.71.e106817

Figure 1 Reduction of Lp-PLA2 production after ACE treatment in mice fed a high-fat, high-fructose diet. The expression of Lp-PLA2 production in mice fed with HFFD and administered ACE was determined from flow cytometry analysis (Fig. 1A). The percentage of Lp-PLA2 production in mice fed with HFFD and administered ACE The data are mean SD (n = 5). N: normal-fed mice (non-high-fat-fructose diet); HFFD: high-fat-fructose diet mice (w/o administration of ACE); D1: HFFD mice receiving ACE 104 mg/kg body weight; D2: HFFD mice receiving ACE 520 mg/gram BW; D3: HFFD mice receiving ACE 5200 mg/kg BW. The different notation on the chart was considered significantly different for each group at p< 0.05 and vice versa on the DMRT post hoc test.

opencc-by-4.0Jan 2024View details →
zenodo28/100

Figure 4 from: Nafisah W, Dalilati AZ, Christina YI, Atho'illah MF, Rifa'ia M, Noor TNETA, Nugraha AP (2024) Amstirdam coffee ameliorates Lp-PLA2 and the inflammatory response in an atherosclerosis rats. Pharmacia 71: 1-8. https://doi.org/10.3897/pharmacia.71.e106817

Figure 4 Administration of ACE increased IL-10 production (CD4+IL-10+) in mice fed with a high-fat, high-fructose diet for 5 months. The expression of CD4+IL-10+ in mice fed with HFFD and administered ACE was determined by flow cytometry analysis (Fig. 4E). The percentage of regulatory cells (CD4+IL-10+) in mice fed with HFFD and administered ACE (Fig. 4F) The data are mean SD (n = 5). N: normal-fed mice (non-high-fat-fructose diet); HFFD: high-fat-fructose diet mice (w/o administration of ACE); D1: HFFD mice receiving ACE 104 mg/kg body weight; D2: HFFD mice receiving ACE 520 mg/kg body weight; D3: HFFD mice receiving ACE 5200 mg/kg body weight. The different notation on the chart was considered significantly different for each group at p < 0.05 and vice versa on the DMRT pos hoc test.

opencc-by-4.0Jan 2024View details →
ClinicalTrials.gov28/100

Blood Pressure Lowering Effect of Supplementation With Korea Red Ginseng Associated With Reductions in Circulating Lp-PLA2 Activity and Lysophospatidylcholines and an Increase in Dihydrobiopterin in P

ClinicalTrials.gov study NCT02326766. IPD Sharing: Not stated. Countries: 0. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Serum Lipid Levels and Lp-PLA2 in Chronic Periodontitis

ClinicalTrials.gov study NCT03041480. IPD Sharing: NO. Countries: 0. Publications: 2.

closedIPD-NOFeb 2026View details →
dryad28/100

Data from: Lp-PLA2 and dual antiplatelet agents in intracranial arterial stenosis

Open the record for dataset details and reuse information.

publicJul 2020View details →
ClinicalTrials.gov24/100

Lp-PLA2 and Coronary Atherosclerosis in Humans

ClinicalTrials.gov study NCT01557088. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician?

ClinicalTrials.gov study NCT01041339. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Dietary Effects on Circulating Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity and Enzyme Activity in Peripheral Blood Mononuclear Cells (PBMCs) in Patients With Prediabetes or Newly Diagno

ClinicalTrials.gov study NCT01895387. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease

ClinicalTrials.gov study NCT01139632. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov20/100

Changes in Body Adiposity by Dual Probiotic Strains Positively Correlated With Changes in Lp-PLA2 Activity in Overweight Adults

ClinicalTrials.gov study NCT02492698. IPD Sharing: Not stated. Countries: 0. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record